^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review
Excerpt:
ICIs used in the studies included an anti-PD-1 antibody (nivolumab) and ananti-PD-L1 antibody (atezolizumab)...Compared to chemotherapy with docetaxel, ICIs improved OS in patients with previously treated KRAS mutant NSCLC (HR = 0.64 [95% CI = 0.43–0.96], P = 0.03) (Figure (Figure2A).
DOI:
10.18632/oncotarget.17594
Source:
Title:
A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy
Excerpt:
...Overall survival (OS)`Progression-free survival (PFS)`Time to next therapy (TTNT)`Best overall response rate (BORR)`Distribution of participant demographics characteristics: Age`Distribution of participant demographics characteristics: Sex`Distribution of clinical characteristics: Smoking status`Distribution of clinical characteristics: ECOG at initial diagnosis and at nivolumab initiation`Distribution of clinical characteristics: Histology`Distribution of clinical characteristics: TNM classification`Distribution of clinical characteristics: Location of metastases`Distribution of clinical characteristics: EGFR mutation`Distribution of clinical characteristics: ALK translocation`Distribution of clinical characteristics: HER2 mutation`Distribution of clinical characteristics: BRAF mutation`Distribution of clinical characteristics: KRAS mutation`Distribution of clinical characteristics: ROS1 mutation`Distribution of clinical characteristics: MET mutation`Distribution of clinical characteristics: PD-L1 expression`Distribution of clinical characteristics: PD-L1 expression on tumor or stromal cells`Incidence of Adverse Drug Reactions`Incidence of Seriousness criteria`Incidence of Intensity/ Grade`Incidence of AE duration`Incidence of Action taken regarding the BMS treatment`Incidence of Incidence rate...
Trial ID:
Source:
Title:
A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC
Excerpt:
...If the pathology is squamous cell carcinoma or the tumor of a known patient has a KRAS mutation, then EGFR and ALK are...
Trial ID:
More C2 evidence
Source:
Title:
NIVORAD - A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy.
Excerpt:
...These may include biomarkers which are often studied amongst patients with non-small cell lung cancer such as PD-L1 expression, EGFR and KRAS mutational status but also novel biomarkers relating to effects of radiation on the immune response. ...
Trial ID:
Less C2 evidence
Source:
Title:
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Excerpt:
To further confirm these observations from a public database, we prospectively collected 20 NSCLC (15 ADC) patients who were treated with pembrolizumab (n = 11) or nivolumab (n = 9) from August 2015 to August 2016 in our center (GLCI)….Patients with TP53 and/or KRAS mutation showed prolonged PFS than both genes negative patients treated with PD-1 inhibitors.
DOI:
10.1158/1078-0432.CCR-16-2554
